CNC

Centene Corp.

Fundamental data last updated:November 17, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Healthcare Plans

Exchange

NYSE

County of HQ

US

Next Earnings Date

02/05/2027

Business Summary

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and services. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual and commercial group. The Other segment operates clinical healthcare and pharmacies, as well as offers vision and dental, behavioral health, and centralized services. It provides services through primary and specialty care physicians, hospitals, behavioral health practitioners, and ancillary providers. The company was founded in 1984 and is headquartered in Saint Louis, Missouri.

 


VALUATION

P/E

23.73

Market Cap ($M USD)

$34.77B

Forward P/E

13.35

PEG

0.15

PRICE TO SALES

0.17

PRICE TO BOOK

1.56

EV / EBITDA

7.83

5-Year Average P/E

Free Cash Flow Yield

11.39%

DCF Value

$111.83

Graham Number

$54.68

Price to FCF

8.78

EV to FCF

7.48

Earnings Yield

4.21%

FCF Yield

11.39%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.96

Next Year EPS Growth Estimate

$5.26

Next Year Revenue Growth Estimate

$200.21B

Return on Equity (ROE)

6.78%

FREE CASH FLOW

Operating Margin

0.50%

Debt-to-Equity

0.70

Piotroski F-Score

8

Altman Z-Score

3.34

Return on Invested Capital (ROIC)

1.91%

Current Ratio

1.16

Quick Ratio

1.16

Net Debt to EBITDA

-1.36

Interest Coverage

1.60

Gross Profit margin

20.18%

FCF PER SHARE

$8.01

REVENUE PER SHARE

$412.62

Gainseekers Quantitative Analysis

Summary

Centene Corp. appears significantly undervalued when juxtaposed against its DCF Value and Graham Number. The stock’s recent pricing indicated it traded well below its intrinsic value, suggesting a potential mispricing by the market. With a Forward P/E of 12.65 and an impressive Altman Z-score of 3.20, the company demonstrates both growth potential and financial stability. The Earnings Yield, although modest, aligns with a conservative risk profile, reinforcing the stock’s appeal for value investors seeking safety and growth.

AI Exposure / Tech Reliance

Operating within the healthcare plans industry, Centene is strategically positioned to leverage AI and tech advancements. The sector's increasing reliance on data analytics and personalized healthcare solutions aligns with Centene's capabilities. This positioning could enhance operational efficiencies and customer engagement, driving long-term resilience.

The Bull Case

For the discerning GARP investor, Centene offers a compelling narrative. The robust Piotroski F-Score of 8 signals strong financial health, while a solid FCF Yield of 12.02% underscores its capital efficiency. Despite a modest ROIC of 2.24%, the company's ability to generate free cash flow suggests effective pricing power and operational management. These factors, combined with a lean operating margin, paint a picture of a company poised for sustainable growth.

The Bear Case

Despite its strengths, Centene is not without vulnerabilities. The Price/Sales ratio of 0.17 and Price/Book of 1.48 may seem attractive, yet the stock's proximity to its 52-week high raises concerns of technical overextension. Additionally, the slim operating margin of 0.61% highlights potential inefficiencies in cost management. Investors should remain cautious of these structural risks, which could hinder future profitability.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$75.43

Institutional Ownership %

1-Year Beta

1.08

Insider Buying % (6 Mo)

Distance to 52-Week High

11.17%

Distance to 52-Week Low

54.97%

EARNINGS SURPRISE %

506.06%

50-DAY SMA

$66.85

200-DAY SMA

$56.21

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.